BG Medicine Says Data from 6,600-Patient Clinical Study Validates CardioScore Cardiac Risk Test | GenomeWeb

By Adam Bonislawski

BG Medicine this week said that data from a clinical validation study of its CardioScore cardiac risk test indicates the test identifies patients at risk of suffering near-term major cardiovascular events with more than double the sensitivity of conventional methods.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.